Health Insurance Literacy and Challenges in Accessing Health Services in Niemann-Pick
NCT ID: NCT04469894
Last Updated: 2020-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
76 participants
OBSERVATIONAL
2020-06-15
2020-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The outcome of this research will be used to inform various other workstreams as NNPDF works to assist families.
The core research objectives are to understand the following from Niemann-Pick patients and their families in the US
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality of Life in Hemophilia by Clinical Scoring System (FISH)Score
NCT04102046
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
NCT01114594
NGS Panel of Incomplete Forms of Ocular Albinism
NCT04495218
Face Anthropometric Pattern Recognition Technology for Computer Aided Diagnosis of Human Genetic Disorders.
NCT00705055
Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.
NCT00154960
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The outcome of this research will be used to inform various other workstreams as NNPDF works to assist families.
The core research objectives are to understand the following from Niemann-Pick patients and their families in the US;
* Level of health insurance literacy through assessment of health insurance terminology, and self-reported insights regarding information seeking, document literacy and cognitive skills
* If they have healthcare insurance, and if not, why not
* Types (including name) of insurance by which Niemann-Pick families are covered
* Information regarding Medicaid Waivers
* Attributes of insurance plans including, but not limited to;
* Deductible amounts for individual and family
* Out of pocket maximums for individual and family
* Insurance premiums
* Associated Health Savings Accounts
* Associated Cost Sharing requirements
* Services, drugs and assistive devices covered
* What the perceived out-of-pocket costs are for Niemann-Pick families (annually)
* When out-of-pocket maximums are perceived to be met for Niemann-Pick families
* Patient and HCP experience in terms of challenges with accessing desired care and coverage
* Where are families experiencing challenges with accessing desired care and coverage? (drugs, assistive devices, services) Is it different for the different phenotypes of the disease?
* What is the challenge? (financial, time, stress, others)
* What is the life impact of that challenge? (work and educational impact, lack or delay of treatment, others)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Niemann-Pick Type A
Also referred to as Infantile Neurovisceral ASMD
No interventions assigned to this group
Niemann-Pick Type A/B
Also referred to as Intermediate form or Chronic Neurovisceral ASMD
No interventions assigned to this group
Niemann-Pick Type B
Also referred to as Chronic Visceral ASMD
No interventions assigned to this group
Niemann-Pick Type C (Early Infantile)
Onset at less than 2 years of age
No interventions assigned to this group
Niemann-Pick Type C (Late Infantile)
Neurodegenerative form (late-infantile) onset at 2-6 years of age
No interventions assigned to this group
Niemann-Pick Type C (Juvenile)
Neurodegenerative form (juvenile) onset at 6-15 years of age
No interventions assigned to this group
Niemann-Pick Type C (Adult)
Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of Niemann-Pick disease, confirmed by membership in the NNPDF or by provision of a proof of disease form
* Able to read, write and communicate in English
* Able to grant informed consent
* Willing to complete a survey and RSVP, and to participate in a 30-minute telephone interview
* Ability to view or receive a document from the interviewer before or during the interview (web browser, ability to receive a text, fax or document by mail)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Engage Health Inc.
INDUSTRY
Icahn School of Medicine at Mount Sinai
OTHER
National Niemann-Pick Disease Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
George A Diaz, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Justin Hopkin, MD
Role: STUDY_CHAIR
National Niemann-Pick Disease Board Chair
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNPDF-BUR001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.